TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25370504

Group type: EXPERIMENTAL
Intervention: Hybrid online training module for panic disorder (PD) based on cognitive behavioral therapy, consisting of six modules over six weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group for six months
Number of subjects: 90
Study: 21678089

Group type: EXPERIMENTAL
Intervention: Educational Innovation (IES) using audiovisual material containing real images of dissected human cadavers
Number of subjects: 303

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 303
Study: 21172765

Group type: EXPERIMENTAL
Intervention: eHealth intervention (Improvehealth.eu)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 46
Study: 17365735

Group type: EXPERIMENTAL
Intervention: Nicotine patch 63 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotine patch 42 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotine patch 21 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15483079

Group type: EXPERIMENTAL
Intervention: Anastrozole (aromatase inhibitor)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11916934

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 9793699

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg + Diazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg + Diazepam 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8561268

Group type: COMPARATOR
Intervention: Intravenous quinine alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous quinine in combination with pefloxacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous quinine alone or in combination with pefloxacin
Number of subjects: 24
Study: 2523210

Group type: EXPERIMENTAL
Intervention: Intravenous injection of amoxycillin/clavulanic acid (1.2 g Augmentin) at induction of anaesthesia (n = 328)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of amoxycillin/clavulanic acid (1.2 g Augmentin) along the line of the proposed incision (n = 296)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 624
Study: 31023758

Group type: EXPERIMENTAL
Intervention: 3 g of metformin daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 28296139

Group type: EXPERIMENTAL
Intervention: BNP and troponin I measurements at admission
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Clinical variables
Number of subjects: 1347
Study: 25482305

Group type: EXPERIMENTAL
Intervention: Combination of 500 mg of naproxen and 20 mg of esomeprazole (test formulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of 500 mg of naproxen and 20 mg of esomeprazole (reference formulation)
Number of subjects: 60
Study: 24023796

Group type: EXPERIMENTAL
Intervention: Scattered site Housing First (HF)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Congregate Housing First (HF)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 67
Study: 20800242

Group type: EXPERIMENTAL
Intervention: Optimized atrioventricular delay (171 ± 8 ms) at interventricular delay of 0 ms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optimized interventricular delay
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optimized pacing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study: 19104358

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 77

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 77
Study: 16755394

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment related to depression severity
Number of subjects: 3559
Study: 12752138

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (311 nm) + calcitriol (twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Narrow-band UVB (311 nm) + dithranol (once daily)
Number of subjects: 10
Study: 10863060

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH) at a dose of 55 Gy/20 fractions/4 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH) at a dose of 64 Gy/32 fractions/6.5 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RTH)
Number of subjects: 35
Study: 9197430

Group type: EXPERIMENTAL
Intervention: gallopamil 150 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: gallopamil 50 mg t.i.d. for 28 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 1443754

Group type: EXPERIMENTAL
Intervention: Training program (2-day basic skills training)
Number of subjects: 266
Study: 3943004

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Rigid sigmoidoscopy
Number of subjects: 293
Study: 29754647

Group type: EXPERIMENTAL
Intervention: mHealth program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 27706451

Group type: EXPERIMENTAL
Intervention: Experimental product (Perlatte(r) - Eurofarma Laboratórios S.A.)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Reference product (Lactaid(r) - McNeilNutritionals, USA)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study: 24893872

Group type: EXPERIMENTAL
Intervention: Vessel-sealing devices (VSDs) - EnSeal, LigaSure, Harmonic
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (ligation and conventional electrocautery)
Number of subjects: 58
Study: 22616409

Group type: EXPERIMENTAL
Intervention: Videotaped instruction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hands-on instruction
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no instruction)
Number of subjects: 27
Study: 20977356

Group type: EXPERIMENTAL
Intervention: n-acetyl-L-carnitine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: lipoic acid + n-acetylcisteine (LA/NAC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: no supplementation
Number of subjects: 61
Study: 18612576

Group type: EXPERIMENTAL
Intervention: Aftercare arm
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Outpatient arm
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Both aftercare and outpatient samples
Number of subjects: 1726
Study: 16094587

Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condylotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disc repositioning
Number of subjects: 0
Study: 11812667

Group type: EXPERIMENTAL
Intervention: Metoprolol 50-100 mg b.i.d.
Number of subjects: 141

Group type: COMPARATOR
Intervention: Xamoterol 100-200 mg b.i.d.
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 141
Study: 10075615

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 234
Study: 7722712

Group type: EXPERIMENTAL
Intervention: High energy, high protein supplement (Atole)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Low energy supplement with no protein (Fresco)
Number of subjects: 663
Study: 2201047

Group type: EXPERIMENTAL
Intervention: M-VAC chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunological agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents or regimens with intensive schedule
Number of subjects: 0
Study: 6787637

Group type: EXPERIMENTAL
Intervention: Fluphenazine HCl
Number of subjects: 29

Group type: COMPARATOR
Intervention: Concomitant use of benztropine mesylate
Number of subjects: 29
Study: 31220872

Group type: EXPERIMENTAL
Intervention: Social norm feedback intervention (letter sent to GPs)
Number of subjects: 221
Study: 27343197

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (6609.0€)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation (7034.7€)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control rehabilitation (4945.2€)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control rehabilitation (13,438.4€)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (36,356€, 51,018€)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (15D-score 0.697)
Number of subjects: 433
Study: 26620402

Group type: EXPERIMENTAL
Intervention: Enhanced women-centred care approach to increase VBAC rates
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 16
Study: 24389434

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily plus pemetrexed 500 mg/m2 intravenously every 3 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 intravenously every 3 weeks plus pemetrexed 500 mg/m2
Number of subjects: 106
Study: 20810005

Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (B-ERP)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (P-ERP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Relaxation training (RELAX)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Exposure treatments (B-ERP and P-ERP)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 135
Study: 18235425

Group type: EXPERIMENTAL
Intervention: Single nasal dose of testosterone; administered in a double-blind, placebo-controlled, crossover manner.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group); administered in a double-blind, placebo-controlled, crossover manner.
Number of subjects: 0
Study: 16581480

Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional echocardiography (RT3DE)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: RT3DE
Number of subjects: 215
Study: 15329381

Group type: EXPERIMENTAL
Intervention: Long-narrow incisor form
Number of subjects: 85

Group type: COMPARATOR
Intervention: Short-wide incisor form
Number of subjects: 85

Group type: COMPARATOR
Intervention: High responder subjects
Number of subjects: 85

Group type: COMPARATOR
Intervention: Low responder subjects
Number of subjects: 85
Study: 11520650

Group type: EXPERIMENTAL
Intervention: SAQ-UK (Seattle Angina Questionnaire - UK version)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: SAQ-UK
Number of subjects: 959
Study: 9497467

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 17
Study: 8402842

Group type: EXPERIMENTAL
Intervention: Gradual inflation protocol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Rapid inflation protocol
Number of subjects: 103
Study: 3781703

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 mcg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28635082

Group type: EXPERIMENTAL
Intervention: Tribal Turning Point (TTP) intervention, 12 group classes and 5 individual sessions
Number of subjects: 62
Study: 27225436

Group type: EXPERIMENTAL
Intervention: Urine specific gravity (USG)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Urine color
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Urine osmolality
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Urine cloudiness
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Additional dipstick measures
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Ability to provide a urine sample
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Volume of a random urine sample
Number of subjects: 313

Group type: COMPARATOR
Intervention: Reference standard: serum osmolality
Number of subjects: 313
Study: 23574529

Group type: EXPERIMENTAL
Intervention: Exenatide 5-μg twice daily
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Exenatide 10-μg twice daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 22051148

Group type: EXPERIMENTAL
Intervention: TAK-875 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-875 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19953660

Group type: EXPERIMENTAL
Intervention: Behavioral intervention group
Number of subjects: 67
Study: 18676932

Group type: EXPERIMENTAL
Intervention: Cormet 2000 Hip Resurfacing
Number of subjects: 337

Group type: COMPARATOR
Intervention: Total Hip Arthroplasty
Number of subjects: 337
Study: 16457083

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2), 45 minutes daily for 10 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group received hyperbaric air for 10 days, followed by HBO2
Number of subjects: 26
Study: 12859697

Group type: EXPERIMENTAL
Intervention: Ibandronate 20 mg/week
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 10849263

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) 3 or 5 million units (MU) three times weekly (t.i.w.) for 3 months, intensified to daily therapy for those with detectable HCV RNA at 3 months.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-α) three times weekly (t.i.w.) for 3 months (control group).
Number of subjects: 222
Study: 8646959

Group type: EXPERIMENTAL
Intervention: Anterior sacral roots stimulator implants
Number of subjects: 8
Study: 1324555

Group type: EXPERIMENTAL
Intervention: norgestimate triphasic (Ortho Tri‐Cyclen, Tri‐Ciles)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: levonorgestrel triphasic (Triphasi)
Number of subjects: 66
Study: 6401927

Group type: EXPERIMENTAL
Intervention: Norethindrone oral contraceptive
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norgestrel oral contraceptive
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of Norethindrone vs Norgestrel
Number of subjects: 21
Study: 31742809

Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 219

Group type: COMPARATOR
Intervention: Paper handout discharge instructions
Number of subjects: 219
Study: 30413727

Group type: EXPERIMENTAL
Intervention: Alkaline drinking water (pH ≈ 9)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Neutral drinking water (pH ≈ 7)
Number of subjects: 29
Study: 27799239

Group type: EXPERIMENTAL
Intervention: Complementary food supplements and dietary counselling
Number of subjects: 1804
Study: 24373063

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 99
Study: 21703973

Group type: EXPERIMENTAL
Intervention: Topical budesonide mouthwash (3 mg/10 mL) applied for 5 or 10 minutes, 2 or 3 times daily
Number of subjects: 0
Study: 19622714

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg qd
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg qd
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coadministration of alogliptin and pioglitazone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glyburide 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg qd with glyburide
Number of subjects: 30
Study: 17484215

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV-6/11/16/18 vaccine
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1781
Study: 15708173

Group type: COMPARATOR
Intervention: Cerivastatin (C)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coenzyme Q(10) (CoQ(10))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combination therapy (Cerivastatin + CoQ(10))
Number of subjects: 25
Study: 11973450

Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Number of subjects: 0
Study: 9657538

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg
Number of subjects: 71
Study: 8210017

Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia (SA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthetic (GA)
Number of subjects: 20
Study: 2690898

Group type: EXPERIMENTAL
Intervention: Oral cyclic estrogen/gestagen (n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral calcium (2000 mg elemental calcium per day) (n = 17)
Number of subjects: 37
Study: 31005917

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 160

Group type: COMPARATOR
Intervention: Flat shoe inserts
Number of subjects: 160
Study: 28314486

Group type: EXPERIMENTAL
Intervention: Insulin provision (IP) therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin sensitizing (IS) therapy
Number of subjects: 2368
Study: 25283522

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg (single infusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg (repeated infusion)
Number of subjects: 32
Study: 23701193

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 μg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 60
Study: 21707217

Group type: EXPERIMENTAL
Intervention: Testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restudying
Number of subjects: 0
Study: 19632624

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 98

Group type: COMPARATOR
Intervention: Minimal ventricular pacing
Number of subjects: 98
Study: 16220495

Group type: EXPERIMENTAL
Intervention: Propensity score‐based multiple imputation (MI) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete-case (CC) method
Number of subjects: 0
Study: 15383187

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (dose titration to achieve LDL-C and non-HDL-C goals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (dose titration)
Number of subjects: 0
Study: 12185636

Group type: EXPERIMENTAL
Intervention: Vitamin A intake
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Carotenoid levels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Retinol levels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Anthropometric evaluation and bone age
Number of subjects: 47
Study: 9868840

Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV, Verorab) according to the 2-1-1 schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV) plus equine rabies immunoglobulins (ERIG, 40 IU/kg body weight) according to the 2-1-1 schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV) plus human rabies immunoglobulins (HRIG, 20 IU/kg body weight) according to the 2-1-1 schedule
Number of subjects: 0
Study: 8091167

Group type: EXPERIMENTAL
Intervention: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days with N-acetylcysteine (NAC) 2 x 600 mg bid (d 21‐30)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days without N-acetylcysteine (NAC)
Number of subjects: 34
Study: 2691409

Group type: EXPERIMENTAL
Intervention: 60-s cycling sprint test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1000-m time trial
Number of subjects: 9

Group type: COMPARATOR
Intervention: 30-s, 40-s, and 60-s cycling sprint tests
Number of subjects: 9
Study: 1130178

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (2,000 IU daily) for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vitamin D or placebo (normal children)
Number of subjects: 25
Study: 30576525

Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29171827

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 30
Study: 26198857

Group type: EXPERIMENTAL
Intervention: Metomidate Hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS‐222
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonanesthetized fish
Number of subjects: 0
Study: 23897903

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with physical training (PT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Physical training (PT) without tDCS
Number of subjects: 9
Study: 21765069

Group type: EXPERIMENTAL
Intervention: 3 doses of IPTp-SP (n = 413)
Number of subjects: 814

Group type: COMPARATOR
Intervention: 2 doses of IPTp-SP (n = 401)
Number of subjects: 814
Study: 19015207

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg plus methotrexate (MTX)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg plus methotrexate (MTX)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 619
Study: 16759926

Group type: EXPERIMENTAL
Intervention: 25 IU weekly increments of rFSH
Number of subjects: 158

Group type: COMPARATOR
Intervention: 50 IU weekly increments of rFSH
Number of subjects: 158
Study: 15295244

Group type: EXPERIMENTAL
Intervention: Etomidate (up to 0.3 mg/kg, n = 7)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etomidate (up to 0.4 mg/kg, n = 17)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pentobarbital (up to 5 mg/kg, n = 33)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 61